I-Mab Biopharma

I-Mab HK is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing novel biologics to address unmet medical needs, particularly in cancer and autoimmune disorders. Established in 2014 and headquartered in Shanghai, China, the company has developed a robust pipeline of drug candidates. These include Felzartamab, an antibody in Phase III trials for multiple myeloma and autoimmune diseases; Eftansomatropin, a long-acting human growth hormone for pediatric growth hormone deficiency; and Olamkicept, an IL-6 blocker in Phase II trials for ulcerative colitis. Additionally, I-Mab HK is advancing several preclinical compounds targeting various diseases, including long-acting therapies for inflammatory bowel diseases and chemotherapy-induced diarrhea. The company has also established a strategic collaboration with AbbVie to develop its CD47 monoclonal antibody, Lemzoparlimab. With a commitment to addressing significant health challenges, I-Mab HK continues to innovate within the fields of immuno-oncology and immuno-inflammation.